Fig. 1From: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort studyOverall survival and progression-free survival of patients treated with apatinib according to the presence of hypertension, proteinuria, or hand and foot syndrome in the first 4 weeks of treatment. a Overall survival. b Progression-free survival. mOS median overall survival; mPFS median progression-free survivalBack to article page